Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HHS Shields Three Ebola Vaccine Makers From Legal Liability

This article was originally published in The Pink Sheet Daily

Executive Summary

GlaxoSmithKline, NewLink Genetics and Johnson & Johnson gain protection for their candidate Ebola vaccines; NewLink teams up with Merck, and GSK prepares for Phase II/III studies in West Africa.

You may also be interested in...



Zika Vaccine Makers, 21st Century Cures Task Force Hit By Regulatory Freeze

HHS asked Federal Register Office to withdraw declaration providing liability immunity to Zika vaccine manufacturers and notice delegating authority under the Cures Act to refine the clinical trials data registry.

Regulatory Briefs: Ebola Trials Protocol, AstraZeneca Resubmits Iressa

FDA officials explain why randomized clinical trials of Ebola products are necessary and the Senate passes Ebola priority review voucher bill. Lilly/AstraZeneca start Alzeimer’s trial, Incyte gains new approval for Jakafi, Sunovion files for new use of Aptiom and AstraZeneca resubmits its once withdrawn lung cancer drug Iressa.

NCI’s Clinical Trial Accrual Is ‘Better’ Than Pharma Industry’s, Director Sharpless Says

NCI networks had vast under accrual in the past year, but Sharpless says industry has been affected to a greater degree. He says the institute also has been better at accruing minority patients.

Topics

Related Companies

UsernamePublicRestriction

Register

PS076800

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel